TWI771317B - 使用藥物基因體學標記的組合物及方法 - Google Patents

使用藥物基因體學標記的組合物及方法 Download PDF

Info

Publication number
TWI771317B
TWI771317B TW106129838A TW106129838A TWI771317B TW I771317 B TWI771317 B TW I771317B TW 106129838 A TW106129838 A TW 106129838A TW 106129838 A TW106129838 A TW 106129838A TW I771317 B TWI771317 B TW I771317B
Authority
TW
Taiwan
Prior art keywords
sequencing
treatment
snp
snps
enzastaurin
Prior art date
Application number
TW106129838A
Other languages
English (en)
Chinese (zh)
Other versions
TW201812125A (zh
Inventor
文 羅
紅 孫
Original Assignee
美商索元生物醫藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商索元生物醫藥有限責任公司 filed Critical 美商索元生物醫藥有限責任公司
Publication of TW201812125A publication Critical patent/TW201812125A/zh
Application granted granted Critical
Publication of TWI771317B publication Critical patent/TWI771317B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW106129838A 2016-09-01 2017-08-31 使用藥物基因體學標記的組合物及方法 TWI771317B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662382734P 2016-09-01 2016-09-01
US62/382,734 2016-09-01
US201662414601P 2016-10-28 2016-10-28
US62/414,601 2016-10-28

Publications (2)

Publication Number Publication Date
TW201812125A TW201812125A (zh) 2018-04-01
TWI771317B true TWI771317B (zh) 2022-07-21

Family

ID=59923555

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106129838A TWI771317B (zh) 2016-09-01 2017-08-31 使用藥物基因體學標記的組合物及方法
TW111122709A TW202313973A (zh) 2016-09-01 2017-08-31 使用藥物基因體學標記的組合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111122709A TW202313973A (zh) 2016-09-01 2017-08-31 使用藥物基因體學標記的組合物及方法

Country Status (15)

Country Link
US (2) US11421280B2 (enExample)
EP (1) EP3507384B1 (enExample)
JP (3) JP7197915B2 (enExample)
KR (1) KR20190046935A (enExample)
CN (1) CN109952383B (enExample)
AU (1) AU2017318669B2 (enExample)
BR (1) BR112019003951A2 (enExample)
CA (1) CA3035386A1 (enExample)
JO (1) JOP20190025A1 (enExample)
MX (1) MX2019002377A (enExample)
PH (1) PH12019500422A1 (enExample)
RU (1) RU2019109011A (enExample)
SG (2) SG11201901762WA (enExample)
TW (2) TWI771317B (enExample)
WO (1) WO2018045240A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN110496223B (zh) * 2018-05-17 2021-09-10 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物
CN112512527A (zh) * 2018-09-12 2021-03-16 杭州索元生物医药股份有限公司 恩扎妥林和btk抑制剂的组合及其用途
CN111549033B (zh) * 2020-06-11 2021-02-12 南京市江宁医院 慢病毒感染人表皮角质细胞株及其构建方法和应用
US11227690B1 (en) * 2020-09-14 2022-01-18 Opendna Ltd. Machine learning prediction of therapy response
CN117642827A (zh) * 2021-07-23 2024-03-01 高雄医学大学 用于评估二代荷尔蒙药物治疗前列腺癌疗效的临床治疗药物预测和推荐系统及方法
US20230131677A1 (en) * 2021-10-21 2023-04-27 Toyota Research Institute, Inc. Systems and methods for predicting the effect of an intervention via machine learning
CN118339312A (zh) * 2021-11-23 2024-07-12 索元生物医药(美国)有限公司 用于评估多核苷酸递送和癌疗法之功效的组合物和方法
US12474842B2 (en) * 2021-12-13 2025-11-18 Google Llc Optimizing data placement based on data temperature and lifetime prediction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
AU2001285047A1 (en) 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
US20040072217A1 (en) 2002-06-17 2004-04-15 Affymetrix, Inc. Methods of analysis of linkage disequilibrium
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
US20080299125A1 (en) 2006-06-05 2008-12-04 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
EP2707498B1 (en) * 2011-01-31 2018-01-17 Denovo Biomarkers Inc. Method for discovering pharmacogenomic biomarkers
BR112013031221A2 (pt) 2011-06-08 2017-01-24 Denovo Biopharma Hangzhou Ltd Co métodos e composições para prever a atividade do modulador de receptor retinóide x
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 Dubois et al., "Next-Generation Sequencing in Diffuse Large B-CellLymphomaHighlights MolecularDivergence and Therapeutic Opportunities: a LYSA Study", Clinical Cancer Research, Vol. 22, AACR, January 27 2016, Pages 2919-2928; *
期刊 Scholtysik et al., "Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis", International Journal of Cancer, Vol. 136, Issue 5, UICC, Jul 22 2014, Pages 1033-1042. *
網路文獻 Denovo Biopharma, Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine", https://denovobiopharma.com/, Sept. 16, 2014/ https://denovobiopharma.com/Denovo_Lilly_News.html; *

Also Published As

Publication number Publication date
JP2020188816A (ja) 2020-11-26
JOP20190025A1 (ar) 2019-02-19
JP2019528705A (ja) 2019-10-17
KR20190046935A (ko) 2019-05-07
JP2022173308A (ja) 2022-11-18
CA3035386A1 (en) 2018-03-08
AU2017318669B2 (en) 2023-04-20
MX2019002377A (es) 2019-09-05
CN109952383A (zh) 2019-06-28
RU2019109011A3 (enExample) 2021-01-22
EP3507384B1 (en) 2023-08-30
BR112019003951A2 (pt) 2019-06-25
CN109952383B (zh) 2024-01-05
SG11201901762WA (en) 2019-03-28
WO2018045240A1 (en) 2018-03-08
JP7197915B2 (ja) 2022-12-28
AU2017318669A1 (en) 2019-03-07
SG10201912134TA (en) 2020-02-27
US20230074781A1 (en) 2023-03-09
US11421280B2 (en) 2022-08-23
PH12019500422A1 (en) 2019-05-27
RU2019109011A (ru) 2020-10-05
US20190233902A1 (en) 2019-08-01
TW201812125A (zh) 2018-04-01
EP3507384A1 (en) 2019-07-10
TW202313973A (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
TWI771317B (zh) 使用藥物基因體學標記的組合物及方法
JP6440658B2 (ja) 薬理ゲノミクスバイオマーカーを発見するための方法
CN103649386B (zh) 预测类视黄醇x受体调节剂活性的方法和组合物
TW202146660A (zh) 用於評估神經傳導物轉運子抑制劑之功效之組合物及方法
US20240417801A1 (en) Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy
HK40011257B (en) Methods and composition for the prediction of the activity of enzastaurin
HK40011257A (en) Methods and composition for the prediction of the activity of enzastaurin
HK40083504A (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
HK1196399B (en) Method for discovering pharmacogenomic biomarkers
HK1196399A (en) Method for discovering pharmacogenomic biomarkers

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees